Compare Crispr Therapeutics AG (CRSP) vs VanEck Video Gaming and eSports ETF (ESPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs VanEck Video Gaming and eSports ETF — how do they compare? Crispr Therapeutics AG trades at $50.43 (market cap $4.97B), while VanEck Video Gaming and eSports ETF trades at $91.42. Which is the better fit depends on your goals.
| CRSP | ESPO | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Sector/Thematic |
52-Week High | $76.78 | $122.30 |
52-Week Low | $44.34 | $85.25 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
ESPO, the VanEck Video Gaming and eSports ETF, trades at $91.78, down 0.62% on the day. Technical indicators show a bullish trend with moving averages signaling strength, though oscillators are neutral and short-term RSI levels suggest overbought conditions. Recent news highlights institutional accumulation and AI-driven profit potential in the gaming sector, with Assetmark Inc. increasing its stake by 35.9% as of its latest 13F filing (SEC, Q1 2026).
The outlook for ESPO is supported by structural growth in digital entertainment and AI efficiency gains, but risks include sector volatility and high valuation multiples. The ETF offers exposure to a high-growth industry, yet investors face concentration risk in gaming stocks and sensitivity to consumer discretionary spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →
